Ardea Biosciences announced that it has initiated a Phase 2b clinical trial of RDEA594 for the management of hyperuricemia and gout. The Phase 2b trial will be a multicenter, randomized, double-blind, placebo-controlled, dose-response study that will evaluate the safety and serum urate-lowering effects of RDEA594 in 140 gout patients with hyperuricemia. The primary efficacy endpoint is the proportion of patients whose serum urate level is <6mg/dL following four weeks of treatment. Initial results are expected by the end of 2009.

RDEA594 is a selective urate transporter 1 (URAT1) inhibitor.

For more information call (858) 652-6500 or visit